Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Chuikyo Recommends Approval of Proposed System Reform for Insurance-Covered Medical Materials
January 4, 2010
- DSP Undertakes Sweeping Reorganization to Enhance Its Presence in CNS Field
January 4, 2010
- New Premium Intended to Strengthen Japanese Pharmas: Mr Kinoshita
January 4, 2010
- CMIC Licenses L-FABP to Roche
January 4, 2010
- Takeda to Copromote Actos with Pfizer in China
January 4, 2010
- Chuikyo Recommends Unification of Revisit Consultation Fee for Clinics and Hospitals
January 4, 2010
- IBL Launches Human Amyloidβ (1-38) Assay Kit
January 4, 2010
- AZ Aims at Top Share for Asthma with Symbicort
January 4, 2010
- DPJ Calls For Net Increases in Medical Fees
January 4, 2010
- No Serious Concern about Safety of New-Type Flu Vaccines Made in Japan
January 4, 2010
- Quintiles to Offer More Risk-Sharing Business Models: Dr Winstanly
January 4, 2010
- 78.1% of Consumers against Exclusion of Poultices from Insurance Coverage: Survey
January 4, 2010
- Eisai Confident of Overcoming Aricept Patent Expiration: Mr Naito
January 4, 2010
- Keidanren Lists Healthcare, Drugs as Major Growth Fields
January 4, 2010
- Multaq Approved by EC for AF: sanofi-aventis
January 4, 2010
- NOF Licenses Polymer-Micelle Carrier Technology from NanoCarrier
January 4, 2010
- H1N1 Vaccine Arepanrix Prequalified by WHO: GSK
January 4, 2010
- Kyowa Hakko Bio to Transfer Domestic Livestock, Aquaculture Business to ASKA
January 4, 2010
- Shionogi: Locusta for Hypercholesterolemia
January 4, 2010
- Cut and Thrust About 2% Price Cut for Long-Listed Drugs at Chuikyo
December 21, 2009
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…